Utility of a circulating tumor DNA test for detecting clinically evident and occult Merkel cell carcinoma: a retrospective study of 23 patients with disease progression on anti-PD-1 therapy

Phase 2 Study of Intratumoral Vidutolimod With Intravenous Checkpoint Inhibitors in Patients With Locally Advanced or Metastatic Merkel Cell Carcinoma (NCT01589977)

Milleted melanoma is a highly potent MDMB inhibitor in TP53 wild-type (p53 WT) models of Merkel cell carcinoma (MCC)

Inhibition potentiates immunogenicity in Merkel cell carcinoma: a promising approach to overcome resistance to anti-PD-1 immunotherapy

Adjuvant avelumab in high-risk Merkel cell carcinoma (MCC) (Induction phase 2), and then once every 120 days until the completion of 720 days (Maintenance phase). Treatment will continue for 2 years in patients without recurrent disease. NCT03721373

Cancer-associated fibroblasts exhibit a pro-angiogenic activity in Merkel cell carcinoma

ADAM Trial: A multicenter, randomized, double-blinded, placebo-controlled, phase 3 trial center setting. The ADAM trial represents the first adjuvant phase 3 trial in MCC and is a major academic collaboration across multiple US cancer centers. Results: Conclusions: Pending.